Navigation Links
VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
Date:4/14/2008

-New Instrument Generates Real-Time In Vivo Data via Quantitative

Tomography-

WOBURN, Mass., April 14 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the commercial launch of its FMT 2500 small animal imaging system. The FMT 2500 is based on VisEn's proprietary Fluorescence Molecular Tomography (FMT(TM)) technology platform, and combined with VisEn's portfolio of fluorescence in vivo imaging agents, enables researchers to rapidly and easily generate quantitative data on key disease biologies and therapeutic response profiles in animal research models. The FMT 2500 launch was announced at the 2008 annual meeting of the American Association for Cancer Research. VisEn has already placed several beta units with leading academic and pharmaceutical customers in the United States and in Europe, and expects to begin commercial deliveries this quarter.

"The key feature of the FMT 2500 is the FMT(TM) technology platform that enables researchers to generate Quantitative Tomographic data in vivo, unlike any other fluorescence imaging technology platform or system on the market," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "Further, due to some breakthrough advances in the system design and FMT software algorithms, this new system generates unmatched data performance, without the need for any index matching fluid. With these performance advances and additional product design improvements, this new system brings the well-validated power of the FMT technology platform to the broader research markets."

The FMT technology platform enables Quantitative Tomographic in vivo data by using three key steps: data generation, data normalization, and fluorescence tomographic reconstruction. The system offers multiplexed imaging capabilities so users can measure, monitor and compare multiple in vivo biologic targets, pathways or processes simultaneously using different fluorescence agents. Using a proprietary FMT 2500 animal imaging cassette that is compatible with multiple imaging modalities, researchers can also co-register FMT data with imaging readouts from other modalities, including CT, MR and PET. FMT image and data outputs can be exported into industry and clinical standard formats, and are DICOM compatible. VisEn also offers a range of fluorescence imaging agents for measuring key biologic targets, pathways and processes in animal models of inflammation, cancer, and skeletal, cardiovascular or pulmonary disease.

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures, Merck Capital Ventures and The Bollard Group. For further information please visit http://www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: